Spherical nucleic acids as an infectious disease vaccine platform

Area of Science:

• Immunology
• Vaccinology
• Nanotechnology

Background:

• The COVID-19 pandemic necessitates rapid development of effective vaccines.
• Spherical nucleic acids (SNAs) offer a promising platform for vaccine delivery.
• Understanding structure-function relationships is key to optimizing vaccine efficacy.

Purpose of the Study:

• To investigate the structure-function relationships of antiviral spherical nucleic acid (SNA) vaccines.
• To evaluate the efficacy of an SNA vaccine targeting the SARS-CoV-2 receptor-binding domain.
• To assess the in vitro and in vivo immune response and protective effects of the developed SNA vaccine.

Main Methods:

• Design and synthesis of SNA nanoparticles incorporating the SARS-CoV-2 receptor-binding domain.
• In vitro testing of vaccine-induced immune cell activation.
• In vivo studies in mice, including vaccination and subsequent lethal viral challenge.

Main Results:

• The SNA vaccine architecture was rapidly developed to target COVID-19.
• The vaccine potently activated human cells in vitro and immune cells in mice in vivo.
• Mice vaccinated with the SNA vaccine exhibited complete survival following a lethal SARS-CoV-2 challenge.

Conclusions:

• Rational vaccine design using SNA technology can yield highly effective antiviral vaccines.
• SNA vaccines targeting specific viral domains are a viable strategy for infectious disease control.
• This study underscores the potential of SNA architecture for rapid response to emerging infectious diseases.